Shark Tank had the power of celebrity to convince viewers that they should care about venture capitalists and startup pitches. It will take a smart social media campaign or a crowdfunded super star (know any?) to get people to watch RealityCrowdTV(Opens in a new window). The idea of getting friends, relatives and strangers to give […]
This is the transcript of my recent podcast(Opens in a new window) with EarlySense’s president, Tim O’Malley.David E. Williams: This is David Williams, president of Health Business Group(Opens in a new window). I’m speaking with Tim O’Malley, president of EarlySense(Opens in a new window).Tim, thanks for joining me today.Tim O’Malley: Thanks, David, for having me […]
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.
The money is still out there, but don’t take it until you absolutely have to. That was the advice to healthcare startups from Fahd M.T. Riaz(Opens in a new window), a partner in Morgan Lewis’s Business and Finance Practice(Opens in a new window). He talked about trends in funding for healthcare startups on a panel […]
A Boston-area startup emerged from the depths of stealth mode today touting a $7 million financing round that will help it move toward clinical trials of a drug that would treat attention-deficit/hyperactivity disorder (ADHD) without addictive side effects.EB-1020, Neurovance Inc.’s lead drug candidate for ADHD, acts on three neurotransmitters: norepinephrine, dopamine and serotonin. Other behavioral […]
(Opens in a new window)North Carolina life science companies hauled in more than $1.1 billion worth of investments and grant money(Opens in a new window) in the last year, according to a report from the North Carolina Biosciences Organization(Opens in a new window).NCBIO, a Durham, North Carolina-based trade group, presented the figures to state legislators […]
(Opens in a new window)Updated 6:47 p.m.Small molecule(Opens in a new window) discovery and development company Akebia Therapeutics Inc.(Opens in a new window) reported positive results from a second Phase 1 clinical trial of its anemia drug, as well as the second closing of a $16 million financing round announced almost a year ago, boosting […]
Employees who enjoy their benefits are more inclined to stay with their company. A 2025 Marsh McLennan Agency report said 73% of employees would remain if plan options were better.
(Opens in a new window)Radiopharmaceuticals company Cellectar Inc.(Opens in a new window) has enrolled the last of eight patients(Opens in a new window) in a Phase 1 trial of its cancer-treating drug candidate.The trial is designed to measure drug safety and dosimetry(Opens in a new window) of Cellectar’s lead compound, called CLR1404. Dosimetry refers to […]
(Opens in a new window)
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
Cellectar Inc. has raised $2.7 million for its radiopharmaceutical technology that treats and detects a variety of cancers, according to a regulatory filing. The company's lead compound is currently in Phase 1 clinical trials for cancer treatment.
The company stated it raised additional money to ensure the development of two of its drugs. Akebia plans later this year to start Phase I clinical trials on an oral medication designed to create new red blood cells in anemia patients. In addition, it wants to establish a human clinical proof of concept for a second drug that prevents vascular leak syndrome, in which blood components leak out of veins and into other systems -- a side effect of some cancer treatments.
John Coffey, NanoBio's vice president for business development, said "we have three of the most significant global pharmaceutical companies in negotiations and they are seriously interested." A deal could come in the next few months.